-

Foldax, Inc. Receives Full Ownership Rights to Proprietary Polymer Patent Portfolio

SALT LAKE CITY--(BUSINESS WIRE)--Foldax® Inc. today announced that it has executed an agreement with Australia’s national science agency, CSIRO, for full ownership of a polymer technology patent family. Foldax has incorporated the polymer technology into its LifePolymer™ materials platform and has conducted testing, which indicates the materials are compatible with blood, with low adherence of proteins, cells, and calcification. This LifePolymer material characteristic makes it highly biocompatible with the human body and extremely durable, which may be ideal for certain medical devices.

Foldax’s initial development with the patented LifePolymer material is for its portfolio of TRIA™ heart valves, which combines the polymer material with valve leaflet design intended to avoid calcification, withstand stresses and strains without failure, and restore patient quality of life without lifelong use of anticoagulant medication.

The LifePolymer technology has undergone extensive biological safety testing that has been included in Foldax’s regulatory filings to the FDA. The TRIA biopolymer heart valve is the first polymer valve ever to receive FDA approval for human studies in both aortic and mitral positions.

“While we believe LifePolymer is ideal for heart valves, we are also excited about the possibility of its application to other medical devices,” said Gregory D. Casciaro, Foldax CEO. “The biocompatible and durable material properties of LifePolymer may make it potentially ideal for drug delivery, orthopedics, glucose monitoring, cardiac cannula, blood pumps, blood oxygenation circuits, vascular, stent coverings, electrophysiology, and non- medical coatings.”

In the case of heart valves, the LifePolymer properties also enable TRIA valves to be the first and only valve robotically manufactured, reducing variability, and allowing for high precision, repeatability, and quality, while substantially improving the economics of manufacturing. Robotic manufacturing could potentially be incorporated in the production of other medical devices designed from LifePolymer, resulting in a robust supply chain and significantly lower manufacturing costs that could be transformative to expanding patient access to life-changing treatments.

The TRIA heart valve and LifePolymer technology are considered investigational and are not available for commercial sale in the U.S.

To learn more about Foldax, visit www.foldax.com.

Foldax Inc. is a medical device company committed to reinventing every aspect of the heart valve – from material to design to manufacturing – to develop surgical and transcatheter valves designed to last a lifetime addressing historical tradeoffs.

Foldax investors include Angel Physicians Fund, Biostar Capital, Caltech, Glenview Capital, Kairos Ventures, Memorial Care Innovation Fund and Sayan Bioventures.

Contacts

Michelle McAdam, Chronic Communications, Inc.
michelle@chronic-comm.com
(310) 902-1274

Foldax, Inc.


Release Summary
Foldax, Inc. receives full ownership rights to the proprietary biopolymer patent portfolio used in its TRIA biopolymer heart valves.
Release Versions

Contacts

Michelle McAdam, Chronic Communications, Inc.
michelle@chronic-comm.com
(310) 902-1274

Social Media Profiles
More News From Foldax, Inc.

Foldax Secures Approval for TRIA Mitral Heart Valve in India

SALT LAKE CITY--(BUSINESS WIRE)--Foldax secured approval for its TRIA mitral heart valve in India....

Foldax® Reports Positive Clinical Results for TRIA Mitral Surgical Heart Valve Using Novel LifePolymer Material

SALT LAKE CITY--(BUSINESS WIRE)--Foldax reported positive 30-day data for the TRIA mitral surgical heart valve using LifePolymer, including favorable safety and hemodynamics....

TRIA™ Polymer Surgical Valves Surpass 200 Patient Life Years

SALT LAKE CITY--(BUSINESS WIRE)--TRIA polymer surgical heart valves from Foldax surpass 200 patient life years, demonstrating durable positive results....
Back to Newsroom